Kala Pharmaceuticals (KALA) Tops Q2 EPS by 3c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($0.70), $0.03 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $2.69 million.

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• Lennar misses estimates as housing headwinds persist
• Lennar Corp. (LEN) Misses Q2 EPS by 1c